the journal of nutrition

behavioural pharmacology

[1] Sodium Intake during Pregnancy, but Not Other Diet Recommendations Aimed at Preventing Cardiovascular Disease, Is Positively Related to Risk of Hypertensive Disorders of Pregnancy.

[2] The effects of Engelhardtia chrysolepis Hance on long-term memory and potential dopamine involvement in mice.

[3] An increasing trend of neonatal invasive multidrug-resistant group B streptococcus infections in southern China, 2011–2017 [Corrigendum]

[4] Association between vitamin D and latent tuberculosis infection in the United States: NHANES, 2011–2012

[5] Evaluating the antimicrobial resistance patterns among major bacterial pathogens isolated from clinical specimens taken from patients in Mofid Children’s Hospital, Tehran, Iran: 2013–2018

[6] A high prevalence of human T-lymphotropic virus (HTLV 1/2) infection among Afro-descendants, Esmeraldas province, Ecuador – need for the implementation of surveys and control programs

[7] Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not – a retrospective cohort study

[8] Spinal brucellosis in Hulunbuir, China, 2011–2016

[9] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[10] Low prevalence of resistance genes in sheltered homeless population in Marseille, France, 2014–2018

[11] Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo

[12] Susceptibilities of Gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections: a 2016–2017 update of the Chinese SMART study

[13] Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016

[14] Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections [Corrigendum]

[15] Silencing of OCH1 unveils the role of Sporothrix schenckii N-linked glycans during the host–fungus interaction

[16] An increasing trend of neonatal invasive multidrug-resistant group B streptococcus infections in southern China, 2011–2017

[17] Epidemiological and molecular analysis of avian influenza A(H7N9) virus in Shanghai, China, 2013–2017

[18] Health care-associated infections – an overview

[19] A multicenter epidemiology study on the risk factors and clinical outcomes of nosocomial intra-abdominal infections in China: results from the Chinese antimicrobial resistance surveillance of nosocomial infections (CARES) 2007–2016

[20] Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem resistant Acinetobacter baumannii bloodstream infections: cefoperazone–sulbactam associated with resistance and tigecycline increased the mortality

[21] In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)

[22] Novel vancomycin–peptide conjugate as potent antibacterial agent against vancomycin-resistant Staphylococcus aureus

[23] Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017

[24] Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections

[25] Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

[26] Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms

[27] Epidemiology of and risk factors for infection with extended-spectrum β-lactamase-producing carbapenem-resistant Enterobacteriaceae: results of a double case–control study

[28] Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015

[29] Current trends to control fungal pathogens: exploiting our knowledge in the host–pathogen interaction

[30] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

[31] Extensively drug-resistant Myroides odoratimimus – a case series of urinary tract infections in immunocompromised patients

[32] Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

[33] Overview of the development of quinolone resistance in Salmonella species in China, 2005–2016

[34] Molecular analysis of multidrug resistance in clinical isolates of Shigella spp. from 2001–2010 in Kolkata, India: role of integrons, plasmids, and topoisomerase mutations

[35] Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections

[36] High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014

[37] Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

[38] Host–pathogen interactions and immune evasion strategies in Francisella tularensis pathogenicity

[39] Staphylococcus aureus – antimicrobial resistance and the immunocompromised child

[40] Update on otitis media – prevention and treatment

[41] Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

[42] Recent developments in the epidemiology and management of tuberculosis – new solutions to old problems?

[43] Combining antihypertensive and antihyperlipidemic agents – optimizing cardiovascular risk factor management

[44] Clinical utility of fixed-combination telmisartan–amlodipine in the treatment of hypertension

[45] Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension – update on clinical utility

[46] Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility

[47] Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

[48] Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma

[49] Prevalence and predictors of left ventricular dysfunction among patients with chronic kidney disease attending Muhimbili National Hospital in Tanzania — a cross-sectional study

[50] Multielectrode phased radiofrequency ablation compared with point-by-point ablation for pulmonary vein isolation – outcomes in 539 patients

[51] Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations

[52] 8-isorpostanes – markers for oxidative stress in obstructive sleep apnea patients with systolic dysfunction

[53] Self-reported prevalence of heart attacks and strokes in Jamaica: a cross-sectional study. The Jamaica Health and Lifestyle Survey 2007–2008

[54] Application of the susceptible–infected–recovered deterministic model in a GII.P17 emergent norovirus strain outbreak in Romania in 2015

[55] The efficacy and safety of ceftaroline in the treatment of acute bacterial infection in pediatric patients – a systemic review and meta-analysis of randomized controlled trials

[56] An increasing trend of neonatal invasive multidrug-resistant group B streptococcus infections in southern China, 2011–2017 [Corrigendum]

[57] Association between vitamin D and latent tuberculosis infection in the United States: NHANES, 2011–2012

[58] Evaluating the antimicrobial resistance patterns among major bacterial pathogens isolated from clinical specimens taken from patients in Mofid Children’s Hospital, Tehran, Iran: 2013–2018

[59] A high prevalence of human T-lymphotropic virus (HTLV 1/2) infection among Afro-descendants, Esmeraldas province, Ecuador – need for the implementation of surveys and control programs

[60] Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not – a retrospective cohort study

[61] Spinal brucellosis in Hulunbuir, China, 2011–2016

[62] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[63] An increasing trend of neonatal invasive multidrug-resistant group B streptococcus infections in southern China, 2011–2017 [Corrigendum]

[64] Association between vitamin D and latent tuberculosis infection in the United States: NHANES, 2011–2012

[65] Evaluating the antimicrobial resistance patterns among major bacterial pathogens isolated from clinical specimens taken from patients in Mofid Children’s Hospital, Tehran, Iran: 2013–2018

[66] A high prevalence of human T-lymphotropic virus (HTLV 1/2) infection among Afro-descendants, Esmeraldas province, Ecuador – need for the implementation of surveys and control programs

[67] Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not – a retrospective cohort study

[68] Spinal brucellosis in Hulunbuir, China, 2011–2016

[69] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[70] Low prevalence of resistance genes in sheltered homeless population in Marseille, France, 2014–2018

[71] Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo

[72] Susceptibilities of Gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections: a 2016–2017 update of the Chinese SMART study

[73] Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016

[74] Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections [Corrigendum]

[75] Silencing of OCH1 unveils the role of Sporothrix schenckii N-linked glycans during the host–fungus interaction

[76] An increasing trend of neonatal invasive multidrug-resistant group B streptococcus infections in southern China, 2011–2017

[77] Epidemiological and molecular analysis of avian influenza A(H7N9) virus in Shanghai, China, 2013–2017

[78] Health care-associated infections – an overview

[79] A multicenter epidemiology study on the risk factors and clinical outcomes of nosocomial intra-abdominal infections in China: results from the Chinese antimicrobial resistance surveillance of nosocomial infections (CARES) 2007–2016

[80] Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem resistant Acinetobacter baumannii bloodstream infections: cefoperazone–sulbactam associated with resistance and tigecycline increased the mortality

[81] In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)

[82] Novel vancomycin–peptide conjugate as potent antibacterial agent against vancomycin-resistant Staphylococcus aureus

[83] Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017

[84] Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections

[85] Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

[86] Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms

[87] Epidemiology of and risk factors for infection with extended-spectrum β-lactamase-producing carbapenem-resistant Enterobacteriaceae: results of a double case–control study

[88] Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015

[89] Current trends to control fungal pathogens: exploiting our knowledge in the host–pathogen interaction

[90] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

[91] Extensively drug-resistant Myroides odoratimimus – a case series of urinary tract infections in immunocompromised patients

[92] Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

[93] Overview of the development of quinolone resistance in Salmonella species in China, 2005–2016

[94] Molecular analysis of multidrug resistance in clinical isolates of Shigella spp. from 2001–2010 in Kolkata, India: role of integrons, plasmids, and topoisomerase mutations

[95] Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections

[96] High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014

[97] Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

[98] Host–pathogen interactions and immune evasion strategies in Francisella tularensis pathogenicity

[99] Staphylococcus aureus – antimicrobial resistance and the immunocompromised child

[100] Update on otitis media – prevention and treatment

[101] Emerging therapies for Clostridium difficile infection – focus on fidaxomicin